Skip to main content

Use of Multiple Sclerosis Drugs Among Pregnant Women

Basic Details
Date Posted
Status
Complete
Medical Product
alemtuzumab
daclizumab
dalfampridine
dimethyl fumarate
fingolimod
glatiramer acetate
interferon beta-1A
interferon beta-1A/albumin
interferon beta-1B
mitoxantrone
natalizumab
peginterferon beta-1a
teriflunomide
Health Outcome(s)
pregnancy
Description

This report contains estimates of multiple sclerosis (MS) drug use before, during, and after pregnancies resulting in a live-born delivery, among women in the Sentinel Distributed Database (SDD). Data from January 1, 2001 to August 31, 2017 from 16 Data Partners contributing to the SDD were included in this report. This request was distributed to Data Partners on November 20, 2017.

Deliverables (1)
Sentinel Modular Program Report: Use of Multiple Sclerosis Drugs Among Pregnant Women
Additional Details
FDA Center
CDER
Analysis Type
Descriptive
Population / Cohort
Pregnant women and women of reproductive age
Data Sources
Sentinel Distributed Database (SDD)
Related Links
2018 ICPE Presentation: Use of Multiple Sclerosis Drugs Among Live Birth Pregnancies in the United States
Sentinel Drug Study: Multiple Sclerosis (MS) Drugs & Exposure Before, During, and After Pregnancy